FOLLOW US

Unfortunately, according to Kalytera, a company that is developing proprietary drugs that use CBD, “there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life.”

Bioavailability is the portion of a drug or substance that can be absorbed and affect the body. Different methods of ingestion will affect the bioavailability. For example, when inhaled CBD has a bioavailability of 31%. In contrast, when it is taken orally, its bioavailability is only 6%.

Kalytera is working to create a new class of CBD drugs with increased bioavailability to deliver more effective doses to patients. They are doing this through research on two fronts.

The first front focuses on further research into the use of CBD. Combining what is already an impressive body of research on the substance with a more in-depth clinical analysis, Kalytera hopes “to expedite regulatory approval and commercialization.” Their CBD research includes several programs that study the efficacy of CBD in bone health and healing for patients with Osteoporosis, bone fractures, Osteogenesis imperfecta, and Prader-Willi Syndrome (PWS).

The second front involves developing and creating synthetic cannabinoids with better bioavailability to deliver more efficient doses.

Kalytera’s research programs study the use of CBD in conjunction with these synthetic cannabinoids in treating patients.

In the 1960’s, Dr. Raphael Mechoulam, an Israeli researcher, was one of the first to successfully identify THC and CBD, the main components of marijuana. His research led him to petition the Israeli Ministry of Health to approve medical marijuana in 1992 and establish a program for researchers and patients, a move which has positioned Israel at the forefront of medical marijuana research.

Kalytera, in efforts to further this research, has partnered with the Hebrew University of Jerusalem and exclusively licensed synthetic cannabinoids KAL 436/9 and 671.

Kalytera researchers have studied the ability of KAL436/9 to improve bone fracture healing and strengthen bones in patients suffering Osteogenesis imperfecta (brittle bone disease).

Researchers are exploring KAL671 for preventing bone loss in mice with PWS.  Thus far, it’s demonstrated the ability to restore bone growth and inhibit bone resorption.  It is also non-toxic in preclinical animal models.

On the 13th of January 2016, Kalytera announced that they have entered a binding letter of intent to acquire securities of Talent Biotechs Ltd., a private Israel-based developer of CBD therapeutics. Under this agreement, they have made a non-refundable payment of $1,000,000. This acquisition will allow Kalytera to further tap into the wealth of Israeli research on medical marijuana.